Remission of HIV myelopathy after highly active antiretroviral therapy.
Staudinger
R
R
Department of Neurology, New York University School of Medicine, NY 10016, USA.
Henry
K
K
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D019888:Nelfinavir / Q000627:therapeutic use; D012074:Remission Induction; D013118:Spinal Cord Diseases / Q000821:virology*; D018119:Stavudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D019259:Lamivudine; D018119:Stavudine; D019888:Nelfinavir